What’s Ahead for BIOMERIEUX 69 MARCY LETOILE ORDINARY SHA (OTCMKTS:BMXMF) After More Shorted Shares?

May 18, 2018 - By Margarite Burden

bioMérieux S.A. (OTCMKTS:BMXMF) Logo

The stock of BIOMERIEUX 69 MARCY LETOILE ORDINARY SHA (OTCMKTS:BMXMF) registered an increase of 9.66% in short interest. BMXMF’s total short interest was 164,600 shares in May as published by FINRA. Its up 9.66% from 150,100 shares, reported previously. With 100 shares average volume, it will take short sellers 1646 days to cover their BMXMF’s short positions. The short interest to BIOMERIEUX 69 MARCY LETOILE ORDINARY SHA’s float is 0.39%.

It closed at $82.05 lastly. It is down 0.00% since May 18, 2017 and is . It has underperformed by 11.55% the S&P500.

bioMérieux S.A. provides in vitro diagnostics solutions that determine the source of disease and contamination to enhance patient health and consumer safety worldwide. The company has market cap of $9.64 billion. The firm offers reagents, instruments, software, and services for diagnosing infectious diseases, healthcare-associated infections, antimicrobial resistance, sepsis, acquired immunodeficiency syndrome, hepatitis, acute care and cardiovascular emergencies, and cancer; and for detecting microorganisms in agri-food, pharmaceutical, biotechnology, and cosmetic products. It has a 33.03 P/E ratio. The Company’s technologies and systems include clinical microbiology products, such as automated VITEK 2 system and Etest for the identification of bacteria and analysis of their susceptibility to antibiotics; VITEK MS, a mass spectrometry system for the identification of bacteria, fungi, and mycobacteria; culture media products; BacT/ALERT for the culture and detection of bacteria present in blood; lab solutions; and molecular diagnostics products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: